Chimeric antigen receptor T cell treatment in hematologic malignancies
TRANSFUSION AND APHERESIS SCIENCE, vol.54, no.1, pp.35-40, 2016 (SCI-Expanded, Scopus)
- Publication Type: Article / Review
- Volume: 54 Issue: 1
- Publication Date: 2016
- Doi Number: 10.1016/j.transci.2016.01.011
- Journal Name: TRANSFUSION AND APHERESIS SCIENCE
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.35-40
- Hacettepe University Affiliated: Yes
Abstract
Adoptive transfer of T cells that have genetically engineered chimeric antigen receptors (CARs) is an encouraging treatment modality in the hematological malignancies. These T cells are capable of selectively recognizing tumor -associated antigens. There are a variety of reported, as well as ongoing studies on the utilization of CART cells in the treatment of leukemia, myeloma, as well as B and T cell lymphomas. In this review, we aimed to highlight current understanding of this promising treatment modality, including its efficacy and adverse effects. (c) 2016 Elsevier Ltd. All rights reserved.